The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) is effective in extensive-stage small cell lung cancer (ES-SCLC), with a higher dose of the drug almost doubling the response rate over a ...
CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...
SCLC incidence decreased by 3% annually from 2000 to 2020, attributed to reduced smoking rates and smoking-related policies. Survival rates for SCLC have shown only minor improvements despite ...
Benmelstobart plus anlontinib with a chemotherapy combination improved survival outcomes for patients with extensive-stage small cell lung cancer. The treatment combination of benmelstobart and ...
Small cell lung cancer (SCLC) remains a highly aggressive malignancy with limited treatment options in the second-line setting, contributing to poor patient outcomes. Advances in therapeutic ...
Imdelltra combined with chemotherapy and PD-L1 therapy showed a 71% objective response rate and 82% disease control rate in ES-SCLC patients. The safety profile was manageable, with severe ...
Circulating tumor DNA (ctDNA) may help personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC), according to a study from China. Researchers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback